What are the risks of anticoagulant therapy during endoscopic retrograde cholangiopancreatography (ERCP), and how can complications like bleeding or clotting be minimized?
Gaurav ChauhanContributor
What are the risks of anticoagulants in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP)?
Share
1. Anticoagulant therapy increases the risk of bleeding during ERCP. To minimize complications, adjusting medication dosage and timing based on consultation with a healthcare provider is crucial.
2. The main risk of anticoagulants during ERCP is bleeding. Preventative measures include temporarily pausing anticoagulants and closely monitoring coagulation parameters before the procedure.
3. Using anticoagulants can lead to bleeding in ERCP. Risk reduction strategies include pre-procedure anticoagulant adjustment and ensuring platelet and coagulation levels are stable.
4. Bleeding is a significant risk with anticoagulant use in ERCP. Lowering this risk involves pausing or adjusting anticoagulants and using local hemostatic measures during the procedure.